3054-11-3

Upstream product

• 1185571-27-0 benzyl {4-[(tert-butoxycarbonyl)amino]phenyl}acetate 
• 1197-55-3 4-aminophenylacetic acid 

Downstream Products

• 395062-84-7 (4-{2-tert-butoxycarbonylamino-3-[4-(pyridin-4-ylmethoxy)-phenyl]-propionylamino}-phenyl)-acetic acid benzyl ester 
• 1185571-31-6 benzyl (4-{[(1E)-1-amino-3-(2,4-difluorophenyl)-3-oxoprop-1-en-1-yl]amino}-phenyl)acetate 
• 1185571-34-9 {4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]phenyl}acetic acid 
• 1185571-33-8 benzyl-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-phenyl}acetate 
• 1185571-72-5 tert-butyl N-({4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]phenyl}acetyl)-2-methylalaninate 
• 1185570-82-4 cyclopentyl N-({4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]phenyl}acetyl)-2-methylalaninate 
• 395062-85-8 (4-{2-{[4-(tert-butoxycarbonylamino-methyl)-cyclohexanecarbonyl]-amino}-3-[4-(pyridin-4-ylmethoxy)-phenyl]-propionylamino}-phenyl)-acetic acid benzyl ester 
• 395062-86-9 (4-{(S)-2-Amino-3-[4-(pyridin-4-ylmethoxy)-phenyl]-propionylamino}-phenyl)-acetic acid benzyl ester 

Relevant academic research and scientific papers

INHIBITORS OF P38 MAP KINASE

Compounds of formula (I) are p38 MAP kinase inhibitors useful for the treatment of autoimmune and inflammatory diseases: wherein: G is -N= or -CH=; D is an optionally substituted divalent mono- or bi-cyclic aryl or heteroaryl radical having 5 - 13 ring members; R6 is hydrogen or optionally substituted CrC3 alkyl; P represents hydrogen and U represents a radical of formula (IA); or U represents hydrogen and P represents a radical of formula (IA); wherein A represents an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5 - 13 ring members; z is O or 1; -X1-L1-Y- is a linker radical or bond; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; and R2 and R3 are as defined in the claims.